BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis

被引：34
|
作者：
Schultheis, B [1 ]
Wang, L
Clark, RE
Melo, JV
机构：
[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Haematol, London, England
[2] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England
来源：
LEUKEMIA | 2003年 / 17卷 / 10期
关键词：
D O I：
10.1038/sj.leu.2403079
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2054 / 2055
页数：3
相关论文
共 50 条
  • [31] Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy
    Haass, Wiltrud
    Kleiner, Helga
    Weiss, Christel
    Haferlach, Claudia
    Schlegelberger, Brigitte
    Mueller, Martin C.
    Hehlmann, Ruediger
    Hofmann, Wolf-Karsten
    Fabarius, Alice
    Seifarth, Wolfgang
    PLOS ONE, 2015, 10 (06):
  • [32] Complex karyotype with a masked Philadelphia translocation and variant BCR-ABL fusion in CML
    Bakshi, Sonal R.
    Patel, Beena P.
    Brahmbhatt, Manisha M.
    Trivedi, Pina J.
    Gajjar, Sarju B.
    Iyer, Ramesh R.
    Parikh, Esha H.
    Shukla, Shilin N.
    Shah, Pankaj M.
    CANCER GENETICS AND CYTOGENETICS, 2009, 189 (02) : 142 - 143
  • [33] Identification of genomic fusion-sites in BCR-ABL positive childhood CML
    Karl, M.
    Krumbholz, M.
    Tauer, J.
    Suttrop, M.
    Metzler, M.
    KLINISCHE PADIATRIE, 2010, 222 (03): : 226 - 226
  • [34] Detection of patient-specific BCR-ABL genomic dna in cml patients with no detectable BCR-ABL by quantitative reverse transcriptase PCR
    Ross, D.
    Bartley, P. A.
    Morley, A. A.
    Seymour, J. F.
    Branford, S.
    Hughes, T. P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 212 - 212
  • [35] e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia
    Roti, Giovanni
    La Starza, Roberta
    Gorello, Paolo
    Gottardi, Enrico
    Crescenzi, Barbara
    Martelli, Massimo F.
    Mecucci, Cristina
    HAEMATOLOGICA, 2005, 90 (08) : 1139 - 1141
  • [36] AML1/MDS/EVI-1 cooperation with Bcr-abl in a murine model for CML blast crisis.
    Wheeler, JC
    Wu, Y
    Zelazny, ET
    Perkins, AS
    BLOOD, 2001, 98 (11) : 468A - 469A
  • [37] Combination Chemotherapy With Tyrosine Kinase Inhibitors Can Overcome Bcr-Abl Mutations In Acute Lymphoblastic Leukemia Or Blast Crisis CML
    Benjamini, Ohad
    Kantarjian, Hagop M.
    O'Brien, Susan
    Thomas, Deborah
    Ravandi, Farhad
    Jain, Preetesh
    Pierce, Sherry
    Borthakur, Gautam
    Kadia, Tapan M.
    Jabbour, Elias
    Estrov, Zeev
    Luthra, Rajyalakshmi
    Cortes, Jorge E.
    BLOOD, 2013, 122 (21)
  • [38] BMS-214662 eliminates CML stem cells and is active against blast crisis CML and cells expressing BCR-ABL kinase mutations.
    Copland, Mhairi
    Richmond, Linda
    Hamilton, Ashley
    Allan, Elaine K.
    Melo, Junia V.
    Holyoake, Tessa L.
    BLOOD, 2006, 108 (11) : 222A - 222A
  • [39] Identification of a rare E6A2 fusion transcript, a variant BCR-ABL1 FISH pattern and cytogenetic evolution in a CML patient who was resistant to Gleevec but responded to AMN107 therapy
    Sebastian, S.
    Naber, J. M.
    Kearney, H. M.
    Lagoo, A. S.
    Gong, J. Z.
    Buckley, P. J.
    Gockerman, J. P.
    Goodman, B. K.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2006, 8 (05): : 638 - 638
  • [40] b3a2 bcr-abl fusion peptides as targets for cytotoxic T cells in CML
    Norbury, LC
    Clark, RE
    Christmas, SE
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 : 69 - 69
12345